Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tevogen Bio Holdings

0.9922
-0.0178-1.76%
Post-market: 0.9775-0.0147-1.48%19:48 EDT
Volume:283.25K
Turnover:279.88K
Market Cap:182.46M
PE:-14.17
High:1.01
Open:0.9984
Low:0.9717
Close:1.01
Loading ...

Company Profile

Company Name:
Tevogen Bio Holdings
Exchange:
NASDAQ
Establishment Date:
2020
Employees:
18
Office Location:
15 Independence Boulevard,Suite #410,Warren,New Jersey,United States
Zip Code:
07059
Fax:
- -
Introduction:
Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.

Directors

Name
Position
Hooman Yazhari
Vice Chairman
Richard N. Peretz
Executive Chairman
Brad Stewart
Independent Director
Parizad Olver Parchi
Independent Director
Paul P. Jebely
Independent Director

Shareholders

Name
Position
Ben Baldanza
Chief Executive Officer
Philippe J. Kurzweil
Chief Financial Officer and Secretary
Jeff Rogers
President